Browse our anti-CD19 (CD19) Antibodies

Human CD19 Molecule (CD19) interaction partners

1. Treatment significantly increased the number of CD19(+)CD24(hi)CD38(hi) B cells.

2. Authors semi-quantitatively classified baseline expression of sCD19 and sCD22 in a large cohort of pediatric B-ALL. Dim CD19 and negative CD22 cases were correlated with common genetic abnormalities.

3. CD3(+)TCRalphabeta(+) and CD19(+) cell-depleted haploidentical or mMUD HSCT is a practical and viable alternative for children with a range of PIDs.

4. CD19ex2vs fail to bind to the key tetraspanin CD81.

5. Multicolor flow cytometry (FCM) effective for minimal residual disease (MRD) detection following CD19-targeted CAR-T cell therapy on B-lymphoblastic leukemia (B-ALL) patients.

6. Patients receiving anti-CD19 therapies demonstrate an increased proportion of CD19-negative progenitors.

7. Here we have developed a novel CAR construct capable of inducing cytokine signaling after antigen stimulation. This new-generation CD19 CAR encodes a truncated cytoplasmic domain from the interleukin (IL)-2 receptor beta-chain (IL-2Rbeta) and a STAT3-binding tyrosine-X-X-glutamine (YXXQ) motif, together with the TCR signaling (CD3z) and co-stimulatory (CD28) domains (hereafter referred to as 28-DeltaIL2RB-z(YXXQ)).

8. CD19 and CD81 were significantly reduced and correlated with disease activity in Systemic Lupus Erythematosus

9. In patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia who failed treatment with blinatumomab, had a minimal change in CD19 expression. At the time of failure, among 61 patients evaluated for immunophenotype, 56 (92%) had CD19-positive blasts; only five (8%) had ALL recurrence with CD19-negative disease. Two patients progressed with lower CD19 expression.

10. a novel mechanism for Dock8 regulation of BCR signaling by regulating cd19 transcription

11. These data suggest that Igbeta and CD19 are part of an alternative B-cell signaling module that use continuous ITAM/PI3K signaling to promote the survival of B lymphoma and normal B cells.

12. Development of Inducible CD19-CAR T cells with a tet-on system for controlled activity and enhanced clinical safety has been reported.

13. diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53.

14. CD4(+) and CD19(+) peripheral lymphocytes of early stage AD patients exhibit mitochondrial depletion, as seen both at the level of DNA and protein

15. The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS).

16. Inhibition of Akt signaling during ex vivo priming and expansion gives rise to CD19CAR T cell populations that display comparatively higher antitumor activity

17. CD19-specific triplebody SPM-1 mediated potent lysis of cancer-derived B cell lines and primary cells from patients with various B-lymphoid malignancies.

18. The increase in CD19+CD24+CD27+ Bregs was closely associated with fasting insulin secretion.

19. The preclinical activity, safety and PK profile support clinical investigation of MGD011 (MGD011 is a CD19 x CD3 DART bispecific protein )as a therapeutic candidate for the treatment of B-cell malignancies

20. this study shows that CD19 isoforms enable resistance to adoptive cellular immunotherapy

Mouse (Murine) CD19 Molecule (CD19) interaction partners

1. The results suggest that CD19 controls the differentiation of marginal zone precursors to marginal zone B cells by regulating ADAM28-mediated Notch2 cleavage.

2. This study demonstrates that antiviral protective antibody-secreting cells (ASC) in the central nervous system are dependent on CD19 activation and peripheral Germinal Center formation, while accumulation of early-recruited IgD(+) B cells is CD19 independent.

3. this study shows that mitochondrial reactive oxygen species suppress humoral immune responses through reduction of CD19 expression and resultant B cell receptor signaling in B cells

4. autoimmunity induced by excessive BAFF production requires B1b B cells and CD19 signaling.

5. WIPF1 deficiency impaired CD19 co-receptor activation and subsequent PI3 kinase signaling, by distorting the actin and tetraspanin networks that lead to altered CD19 cell surface dynamics.

6. Syk-deficient B cells require BAFF receptor and CD19/PI3K signaling for their long-term survival.

7. The selection of mature B cells is critically dependent on the expression level of the co-receptor CD19.

8. This inhibitory function of FcgammaRIIB in impairing the spatial-temporal colocalization of BCR and CD19 microclusters in the B cell immunological synapse may help explain the hyper-reactive features of systemic lupus erythematosus

9. These results show that the ability of CD19-CAR T-cells to home in on tumor lesions is pivotal for their anti-tumor effects in our xenograft models, and therefore may enhance the efficacy of adoptive T-cell therapy for refractory B-cell lymphoma.

10. Data show that effective B cell receptor (BCR) signaling requires collaboration with the coreceptor CD19 organized by the CD81-tetraspanin network.

11. results indicate that the CD19/CD81 complex interacts with CD38 but this interaction is not required to induce proliferation in mouse B lymphocytes

12. CD19positive CD45R(lo)positive lymphocytes of embryonic origin are present in Peyer's patches and in the spleen throughout the life span of wild-type mice, beginning at postnatal day 7.

13. We report that regulatory dendritic cells can induce splenic B cells to differentiate into a distinct subtype of IL-10-producing regulatory B cells with unique phenotype CD19(hi)FcgammaIIb(hi).

14. CD19 is a major BCR-independent regulator of MYC-driven neoplastic growth in B cell neoplasms.

15. Data from transgenic/knockout mice indicate that CD19 is not required for generation of marginal zone B-cells under influence of Notch2 signaling; data confirm that in absence of CD19, all B cells shift to marginal zone B-cell compartment.

16. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes CD19 can eradicate lymphoma and normal B cells.

17. CD19 expression has both protective and disease promoting roles in lupus pathogenesis in New Zealand black (NZB) and in New Zealand white F1 hybrid (NZB/W) mice deficient for CD19 (CD19-/-).

18. BCR engagement induced differential Tyr phosphorylation. Y(513) phophorylation occurred 1st; Y(482) phosphorylation was delayed & transient. This affected CD19-mediated downstream pathways. Phosphorylation differed with the plasma membrane location.

19. Ca(2+) down-regulates SLC and CD19 gene expression upon pre-BCR activation through inhibition of E2A by Ca(2+)/calmodulin.

20. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse

Cow (Bovine) CD19 Molecule (CD19) interaction partners

1. DNA sequence analysis of the coding sequence of CD19, the CR2 co-signaling molecule.